MedPath

Tumor Absorbed Dose-Response Relationship in Patients Treated With 177Lu-DOTATATE for Meningioma

Completed
Conditions
Meningioma of Brain
Registration Number
NCT06614205
Lead Sponsor
Central Hospital, Nancy, France
Brief Summary

The hypothesis for this study is that there is a dose-response relationship in patients treated with 177Lu-DOTATATE for meningiomas.

Detailed Description

Dosimetry is essential for Peptide Receptor Radionuclide Therapy (PRRT) of meningiomas, to predict efficacy and dose-effect relationships at the individual level, and to move towards personalized medicine. Due to the increasing therapeutic applications of Lutathera, the European Association of Nuclear Medicine (EANM) recently issued recommendations on the dosimetry of 177Lu-labeled somatostatin analogues. Nevertheless, despite these recommendations, the evaluation of meningioma tumor dosimetry in Peptide Receptor Radionuclide Therapy studies is not systematic, which has not enabled us to clearly determine the dose delivered to the meningioma lesion in these treatments and the possible dose-response relationship in this type of treatment.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
11
Inclusion Criteria
  • patients treated for menigioma at nancy hospital
  • patients who performed 3 scintigraphics exams during there treatment
Exclusion Criteria
  • patients deprived of liberty
  • patient who refused to collect data retrospectively

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Diagnostic accuracy for progression free survivalDay 1

Accuracy of tumor dosimetry to predict 6-month progression-free survival.

Secondary Outcome Measures
NameTimeMethod
Diagnostic accuracy for overal survivalDay 1

Accuracy of tumoral dosimetry in predicting 6-month overall survival

Trial Locations

Locations (2)

CHRU de NANCY

🇫🇷

Vandoeuvre les Nancy cedex, France

Nuclear medicine Department CHRU de NANCY

🇫🇷

Vandoeuvre les Nancy cedex, France

CHRU de NANCY
🇫🇷Vandoeuvre les Nancy cedex, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.